CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and moderate symptoms of COVID...
Phase 2
New Haven, Connecticut, United States and 6 other locations
multi-center clinical trial (RCT) of SPI-1005 in adult subjects with positive PCR test for novel SARS-CoV-2 (nCoV2) and severe symptoms of COVID...
Phase 2
New Haven, Connecticut, United States and 6 other locations
The proposed trial will obtain preliminary data on the feasibility of studying RTB101 as compared to placebo for COVID-19 post-expo...
Phase 2
Farmington, Connecticut, United States and 1 other location
vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19).In order to represent a more recently circulating SAR...
Phase 2
Waterbury, Massachusetts, United States of America and 144 other locations
This is a Phase 4, post-market US study, evaluating the efficacy and safety of a single dose of the NVX-CoV2705 Omicron JN.1 COVID-19...
Phase 4
Milford, Connecticut, United States and 98 other locations
The purpose of this study is to learn about the safety, tolerability, and immunogenicity of an updated vaccine against COVID-19.Thi-...
Phase 3
Milford, Connecticut, United States and 18 other locations
study treatment works in the study) of the study medicine (called nirmatrelvir/ritonavir) for potential treatment of coronavirus disease 2019 (COVID...
Phase 3
East Setauket, New York, United States and 75 other locations
studies or substudies based on age group and prior history of COVID-19 vaccinations. All participants in each of the 5 sub-studies ...
Phase 3
New Haven, Connecticut, United States and 100 other locations
The purpose of this study is to learn about the safety and effects of the vaccine (called COMIRNATY) for the potential prevention of COVID-19...
Phase 4
Hartford, Connecticut, United States and 17 other locations
the efficacy and safety of mRNA-1283 and mRNA-1273 (variant formulations) in adults 50 to 64 years of age without high risk factors for severe COVID...
Phase 4
Bridgeport, Connecticut, United States of America and 149 other locations
Clinical trials
Research sites
Resources
Legal